Replimune Group Inc. (REPL)
10.39
-0.06 (-0.57%)
At close: Mar 28, 2025, 3:59 PM
10.46
0.65%
After-hours: Mar 28, 2025, 07:50 PM EDT
-0.57% (1D)
| Bid | 10.32 |
| Market Cap | 800.18M |
| Revenue (ttm) | 3.73M |
| Net Income (ttm) | -210.52M |
| EPS (ttm) | -3.08 |
| PE Ratio (ttm) | -3.37 |
| Forward PE | -6.29 |
| Analyst | Buy |
| Ask | 10.47 |
| Volume | 248,811 |
| Avg. Volume (20D) | 723,756 |
| Open | 10.46 |
| Previous Close | 10.45 |
| Day's Range | 10.11 - 10.48 |
| 52-Week Range | 4.92 - 17.00 |
| Beta | 1.30 |
About REPL
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Pha...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 20, 2018
Employees 331
Stock Exchange NASDAQ
Ticker Symbol REPL
Website https://www.replimune.com
Analyst Forecast
According to 6 analyst ratings, the average rating for REPL stock is "Buy." The 12-month stock price forecast is $18.5, which is an increase of 78.06% from the latest price.
Stock Forecasts2 months ago
+9.87%
Replimune Group shares are trading higher after HC...
Unlock content with
Pro Subscription
2 months ago
+16.86%
Replimune Group shares are trading higher after the company announced the FDA has accepted the biologics license application for RP1 in combination with nivolumab for patients with advanced melanoma
